Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


Shares of NovaBay Pharmaceuticals Inc. (NBY) are surging over 42% in pre-market today, after the company announced testing results from an independent third-party laboratory confirming that Avenova, NovaBay's proprietary formulation of pure hypochlorous acid, kills SARS-CoV-2.


RTTNews | Jul 13, 2020 09:05AM EDT

09:04 Monday, July 13, 2020 (RTTNews.com) - Shares of NovaBay Pharmaceuticals Inc. (NBY) are surging over 42% in pre-market today, after the company announced testing results from an independent third-party laboratory confirming that Avenova, NovaBay's proprietary formulation of pure hypochlorous acid, kills SARS-CoV-2.

As previously announced, NovaBay continues to work with the U.S. FDA on the Emergency Use Authorization or EUA for the fluorecare SARS-CoV-2 IgG & IgM Antibody Combined Test Kit. The FDA has not provided a timeline for completion of the review, the company added.

The stock has been trading in the range of $0.24 - $1.85 for the past one year, and closed Friday's trade at $1.13, down 2 cents or 1.74%. NBY is currently trading at $1.62, up 48 cents or 42.11% in the pre-market session.

Read the original article on RTTNews ( https://www.rttnews.com/3110511/stock-alert-novabay-pharma-shares-soar-42-in-early-trade.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC